Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha‐fetoprotein levels

BACKGROUND AND AIMS: Regorafenib has demonstrated its survival benefit for unresectable hepatocellular carcinoma (uHCC) patients in a phase III clinical trial. We aimed to assess the efficacy and tolerability of regorafenib and the predictors of treatment outcomes in Taiwanese patients. METHODS: We...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Po‐Yao, Cheng, Tzu‐Sheng, Chuang, Shih‐Chang, Chang, Wen‐Tsan, Liang, Po‐Cheng, Hsu, Cheng‐Ting, Wei, Yu‐Ju, Jang, Tyng‐Yuan, Yeh, Ming‐Lun, Huang, Ching‐I, Lin, Yi‐Hung, Wang, Chih‐Wen, Hsieh, Ming‐Yen, Hou, Nai‐Jen, Hsieh, Meng‐Hsuan, Tsai, Yi‐Shan, Ko, Yu‐Min, Lin, Ching‐Chih, Chen, Kuan‐Yu, Dai, Chia‐Yen, Lin, Zu‐Yau, Chen, Shinn‐Cherng, Huang, Jee‐Fu, Chuang, Wan‐Long, Huang, Chung‐Feng, Yu, Ming‐Lung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704159/
https://www.ncbi.nlm.nih.gov/pubmed/34786871
http://dx.doi.org/10.1002/cam4.4430

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704159/
https://www.ncbi.nlm.nih.gov/pubmed/34786871
http://dx.doi.org/10.1002/cam4.4430

Ejemplares similares